Recent news highlights Odyssey Health's strategic moves including securing a multi-million-dollar, nine-year service contract and financing facility, and entering the breast cancer marketplace. These developments reflect ongoing efforts to advance its product portfolio and financial position.

• Odyssey Health secured a multi-million-dollar, nine-year service contract and financing facility for up to $25 million as of November 19, 2025 [N1].
• The company entered the $26 billion breast cancer marketplace as announced on October 16, 2025 [N2].
• Odyssey Health is advancing development of its Save A Life choking rescue device as of August 26, 2025 [N3].
• The company strengthened its balance sheet with $8.7 million in net equity as reported in March 2024 [N4].
• Odyssey Health closed the asset sale of its neurological drug technology pipeline including a concussion drug candidate with Oragenics, Inc. in January 2024 [N5].
• The company has presented concussion treatment data at military and special operations medical symposia in 2023, indicating ongoing clinical development efforts [N6].
• Odyssey Health is preparing for a Phase II pharmaceutical concussion treatment as of March 2023 [N7].
• The company formed a community-based partnership for military concussion research in February 2023 [N8].

Odyssey Health has developed unique medical technologies targeting unmet clinical needs, including devices for heart monitoring and choking rescue. The company has demonstrated progress in clinical trials for a concussion drug and has formed strategic partnerships and subsidiaries to advance neurological disease treatments. Securing a multi-million-dollar service contract and financing facility provides financial support for ongoing development. If the company successfully obtains regulatory approvals and commercializes its products, it could establish a foothold in sizable medical markets such as breast cancer and neurological disorders.

Odyssey Health currently has no approved products and has not generated revenue, reflecting its early-stage development status. The company faces significant liquidity constraints, with a current ratio of 0.04 and cash equivalents of only $3,186 as of April 30, 2026. It relies heavily on debt and equity financing, which may dilute shareholders or increase financial risk. Regulatory approval processes are uncertain and costly, and clinical trial outcomes may not be favorable. The company also faces competition from established medical device and pharmaceutical companies, and its ability to protect intellectual property is uncertain. These factors pose substantial risks to its business viability and growth prospects.

Odyssey Health's moat is limited given its early-stage development status, lack of commercial products, and reliance on regulatory approvals. Its potential competitive advantages lie in its proprietary technologies under development, such as the CardioMap device and Save-A-Life choking rescue device, and its focus on unmet medical needs. The company's ability to secure patents and intellectual property protection, as well as successful clinical trial outcomes, will be critical to establishing a defensible position. However, the company faces significant risks from competition, regulatory hurdles, and financing challenges that may impact its ability to realize these advantages.

• Regulatory Approval Risk: Odyssey Health's products require FDA and other regulatory clearances or approvals before commercialization. The timing, costs, and outcomes of these regulatory processes are uncertain and may delay or prevent product launches.
• Financing and Liquidity Risk: The company has significant liquidity constraints with a current ratio of 0.04 and limited cash reserves. It depends on obtaining additional financing through debt or equity, which may not be available on favorable terms or at all.
• Clinical Development Risk: The success of the company's product candidates depends on the results of clinical trials, which are inherently uncertain and may not demonstrate safety or efficacy.
• Intellectual Property Risk: Odyssey Health's ability to obtain, maintain, and enforce patents and other intellectual property rights is critical to its competitive position. Failure to do so could allow competitors to enter the market.
• Market and Competitive Risk: The company operates in competitive medical markets with established players. Emerging competing technologies and adverse market developments could impact its business.

• Odyssey Health, Inc. is a medical-related product development company focused on acquiring and developing unique medical technologies and products.
• The company’s business model involves developing or acquiring medical products, engaging third parties for development and manufacturing, and distributing products through various channels including third parties.
• Currently, Odyssey Health has two technologies in research and development: the CardioMap heart monitoring and screening device, and the Save-A-Life choking rescue device.
• None of the company’s product candidates have received regulatory clearance or approval for commercial sale as of the latest filings.
• The company plans to license and develop products upon receiving adequate funding and intends to apply for trademarks and patents as products advance.
• Odyssey Health is not currently selling or marketing any products; FDA clearance or approval is required to market products in the U.S., and additional approvals are needed for international sales.
• The company has experienced no revenue for fiscal years 2024 and 2025, reflecting its development-stage status.
• Odyssey Health had an accumulated deficit of approximately $62.7 million as of July 31, 2025.
• The company reported a net loss of approximately $1.74 million for fiscal year 2025, a worsening from the prior year.
• Research and development expenses were zero in fiscal 2025, down from $55,166 in fiscal 2024, indicating no active projects during that period.
• General and administrative expenses decreased by 51% to about $1.02 million in fiscal 2025, reflecting lower salaries and business activity.
• The company completed a sale of neurological drug technology assets to Oragenics, Inc. in December 2023, which generated a significant gain in fiscal 2024 but no gain in fiscal 2025.
• Odyssey Health has outstanding convertible notes and promissory notes with various investors and officers, with amendments extending maturity dates into 2026.
• The company’s liquidity position as of April 30, 2026, shows cash and equivalents of $3,186 and current assets of $373,779 against current liabilities of $10,123,436, resulting in a current ratio of 0.04 and a cash ratio of 0, indicating significant liquidity constraints.
• Odyssey Health entered into a multi-million-dollar, nine-year service contract and financing facility for up to $25 million as of November 2025.
• The company has engaged in clinical trials and development activities related to a pharmaceutical concussion treatment, including positive Phase I trial results and preparations for Phase II.
• Odyssey Health has formed partnerships and subsidiaries focused on neurological diseases and military concussion research.
• The company’s principal address is in Las Vegas, Nevada, and it trades on the OTC Markets under the symbol 'ODYY'.
• There are approximately 534 stockholders of record as of October 29, 2025, with about 99.85 million shares outstanding.
• The company has not paid dividends and does not currently plan to do so, retaining earnings to finance growth.
• The Board of Directors oversees cybersecurity risks and receives annual updates on the company’s cybersecurity program.
• Odyssey Health’s financial statements are prepared in accordance with U.S. GAAP and include estimates and judgments by management.
• The company faces risks including limited operating history, lack of revenue, ability to obtain financing, regulatory approvals, clinical trial outcomes, intellectual property protection, and market competition.
• There have been no material changes to risk factors during the nine months ended April 30, 2026.
• Recent news includes the company securing a multi-million-dollar service contract and financing facility, and entering the $26 billion breast cancer marketplace, among other developments [N1][N2][N3][N4][N5][N6][N7][N8][S1][S2].